QP release and batch disposition, explained.

Why 48,210 finished syringes wait in a locked part of the warehouse until one person signs

From the last filled syringe to stock a warehouse may pick

1. The batch is madeEvery step is recorded. The stock goes straight into quarantine.
2. The lab tests itSterility alone takes 14 days in the fictional case here. Results are approved one by one.
3. The evidence is checkedRecords, investigations, changes, clean-room data and market approvals are gathered, and open items are closed.
4. A person decidesThe QP certifies, or the US quality unit approves, or the batch is held or rejected.
5. The stock movesThe warehouse status changes for the markets covered, and the record stays open to inspectors.

Steps 3 and 4 are the subject of this guide.

A QP cannot hand over the duty, and three more surprises about batch release

Qualified Person, certification, disposition, quarantine

Fourteen terms are defined in the one-page summary.

Batch release has three acts in EU GMP: checking the batch, certifying it and moving it to saleable stock

In shortPeople use "release" for three different things. EU GMP Annex 16 separates them: the checking, the QP's certification, and the transfer to saleable stock. Keeping them apart tells you who is responsible for what, and what software may and may not do.

The purpose is written into the annex: to ensure the batch was made and checked as its marketing authorization (the license for a market) and GMP require, that other legal requirements are met, and that if a batch has to be recalled, the QPs and records involved "are readily identifiable".4 The last point explains why the register matters so much. It answers, years later, who said this batch could go, and on what basis.

Who may be a Qualified Person

Directive 2001/83/EC sets the bar. A QP holds a university qualification, normally of at least four years, in pharmacy, medicine, veterinary medicine, chemistry, pharmaceutical chemistry and technology, or biology, with a defined list of subjects. A QP also has "practical experience over at least two years", which a longer course can shorten, in authorized manufacturers, in qualitative and quantitative analysis and the checks needed for quality.1 Member states enforce the duties through administrative measures or a professional code, and may suspend a QP when proceedings begin.1

A QP must also know the work personally. Annex 16 asks for "detailed knowledge of the steps for which they are taking responsibility" and proof of continuous training on the product type, processes, technical advances and GMP changes.4 Where several sites are involved, one QP can confirm a stage and another certify the finished batch, and a written agreement says who carries what. The QP performing final certification "holds overall responsibility", in the words of the European Medicines Agency (EMA) in its questions and answers.8

The words buyers search for, and what each means

The rules on QP certification and US quality unit approval, with their status on November 3, 2026

In shortThe core texts are stable: Directive 2001/83/EC Article 51, Annex 16 in its 2015 revision and, as of the 2025 edition of the US Code of Federal Regulations (CFR), 21 CFR 211.22 and 211.192. What has moved is around them: Annex 1 for sterile products, the Windsor Framework (the UK-EU agreement covering Northern Ireland), a December 2025 EMA answer on batches outside the EU, and a draft EU annex on AI. The EU pharma package is still not law.

What a QP must have secured before certifying: EU GMP Annex 16's 21 points in plain words

In shortAnnex 16 lists three duties the QP "must personally ensure" and 21 points the QP must have secured, any of which may be delegated as a task. The list reaches well beyond the batch record: audits, supply chain diagrams, active substance rules, self-inspection and shipping all count.

Section 1.6 lists the personal duties: certification is permitted under the manufacturing authorization, national requirements are met, and certification is recorded in a register.4 Section 1.7 then says the QP "has responsibility for ensuring points 1.7.1 to 1.7.21 are secured", that these tasks may be delegated, and that the QP relies on the pharmaceutical quality system and "should have on-going assurance that this reliance is well founded".4 We read that last clause as a duty to keep checking the system, as well as the batch.

The paraphrases are ours, shortened for reading. Use the annex's own wording in your procedures.4

What may be handed to someone else, and what stays with the QP

How EU QP certification and US quality unit batch approval differ in law and on the desk

In shortBoth protect the same moment. The EU names a qualified individual who answers for the batch and signs a register. The US gives authority to a unit within the firm, and asks it to review records and investigate discrepancies before release. Global plants usually run one evidence file and two signatures.

A batch for the EU and a batch for the US from the same plant can share nearly all their evidence and still need different lines: an EU license against a US biologics license application (BLA) or new drug application (NDA), a hub upload against trading-partner data, and a different person and meaning on the signature.

The seven systems behind one batch release file and the three documents that come out of it

In shortA release file is assembled from at least seven kinds of system, each with a different owner. Three documents leave at the end: the entry in the certification register, the batch certificate, and for shared steps a QP confirmation. The content of the last two is set out in Annex 16's appendices.

The same survey found four elements seen as essential by over 90% of QPs when working away from site: batch records, QC results, relevant deviations and out-of-specification reports. Fewer than 80% said the same for the relevant parts of the marketing authorization and related changes.23 Yet market and license questions are where a batch can end up in the wrong place.

When a QP may certify after an unexpected deviation: the Annex 16 section 3 test worked through on a late bulk hold

In shortA batch can still be certified after something unexpected happens, on conditions. All registered specifications must be met, the cause must be investigated, a risk process must conclude the impact is negligible, and the QP must consider extra stability. Failing a registered specification closes this route. Planned deviations were never on it.

The worked case: formulated bulk held 26 hours 40 minutes against a 24-hour limit

Here is the fictional case used throughout this guide. On September 18, 2026, at 9:40 pm, a stopper bowl on a filling line jammed. Filling stopped for 3 hours 10 minutes while a feeder was realigned. The formulated bulk, the finished solution waiting to be filled, stayed at 2–8 °C for 26 hours 40 minutes from the end of formulation to the end of filling. The batch record's limit was 24 hours, so this was a major deviation, DEV-26-1187.

What environmental monitoring means for certifying a sterile batch: Annex 1's limits and a settle plate at 6 CFU

In shortFor sterile products, passing the sterility test is the last check in a chain and cannot stand in for the rest. EU GMP Annex 1 says monitoring data and trends "should be reviewed as part of product batch certification/release", and excursions should be investigated before certification. So a closed investigation still comes to the person signing.

A sterility test samples a tiny share of a batch. Annex 1 says it "should only be regarded as the last in a series of critical control measures" and "cannot be used to assure sterility of a product that does not meet its design, procedural or validation parameters".12 The rest of the assurance comes from the process, and from the clean-room data taken while the batch was made.

Among those data are settle plates, dishes of growth medium left open to catch microbes falling from the air. Annex 1 grades clean rooms from A, the strictest, to D.12

Working through one plate on the fill day

In the fictional case, settle plate B-07 in room F-214, Grade B, read 6 CFU per 4 hours on September 18 against the limit of 5. That is one colony over. The organism was Micrococcus luteus, identified to species as Annex 1 expects for Grades A and B.12 All 46 Grade A samples read 0 CFU, gloves and gowns read 0, and investigation EM-26-0311 closed on October 3 with no impact on the batch, plus gowning retraining for one operator.

What FDA has written about sterile batches and release, in 2026 letters

A warning letter, FDA's formal notice of significant violations, states FDA's position at its date; a firm may have responded or corrected since. The letters are cited only for the sentences quoted.

Why a batch's certificate may be narrower than its order: market-by-market approvals, changes and serial numbers

In shortA batch must match the license of every market it goes to, and licenses change on different dates. A change approved in the EU and pending in Canada means the batch cannot go to Canada. Annex 16 asks that manufacture and testing match the license, and that change impact is evaluated. Serial data must be in place before release too.

Annex 16 points 1.7.4, 1.7.5 and 1.7.15 say sites must comply with the marketing authorization "for the intended territory", activities must be "consistent with those described" in it, and "the impact of any change" must be evaluated.4 The batch certificate names the destination countries, at least within the EU.4 In the fictional case, batch VL26-0418 is the first to use stoppers from a second-source supplier. The sample change record shows four markets on four clocks.

The EU's system for license changes, called variations, moved too: chapter codes became E, Q, C and M from January 15, 2026, under guidelines C/2025/5045.26 A stored procedure that quotes old B.II codes needs a look. In the US, 21 CFR 601.12(c) covers the 30-day supplement for biologics.9

Quality unit oversight and investigations are FDA's two most cited drug manufacturing sections in fiscal 2025

In shortBy our count of FDA's published data, 21 CFR 211.22 and 211.192 were the two most cited Part 211 sections on Form 483s, FDA's list of observations at the end of an inspection, in fiscal 2025. Their counts roughly doubled from fiscal 2020 as the number of drug Form 483s doubled, so the rate per form stayed about level. Warning letters show what that looks like: batches released before the records were reviewed, or before a question was answered.

When a batch that should have waited has already shipped

Six common errors on the release desk, and why they happen

What a day in quarantine costs, and how little batch release lead time data is published

In shortPublished numbers here are thin and mostly come from vendors, and we mark them that way. We found no independent benchmark for hours per certification or days from made to certified. The arithmetic for your own site is simple: value in quarantine, multiplied by your carrying rate, divided by 365.

Working out a day's carrying cost in quarantine

A company's money is tied up in stock it cannot sell. One way to value a day is the batch's value at cost or transfer price, multiplied by the annual rate your finance team uses for inventory, divided by 365. The rate here is an assumption to replace.

The carrying cost is usually the smaller part of the case. A batch that misses its need date can mean a market out of stock. That is why planners watch this work closely.

FDA's report gives no link between shortages and release lead time, and neither do we. It does show release acting as a control under pressure: to prevent or ease shortages in 2025, FDA used regulatory flexibility 78 times, and one example was "extra testing for product quality" before release.37

What regulators say about AI near a batch release decision, and the line draft Annex 22 draws

In shortThe law names a person for this signature, and no text we read changes that. Draft EU GMP Annex 22 goes further: it says generative AI and large language models "should not be used in critical GMP applications". It is still a draft, and EMA's June 2026 report describes the drafters discussing a wider scope. Any company using such models near release needs a dated, written position.

Who touches a batch before certification: the QP, QA, QC, regulatory, suppliers and the planner waiting on them

In shortRelease is a relay among six or more roles, and most of the waiting sits at the hand-offs. Common setups run from a paper checklist to a release module on a quality or ERP suite. All of them still need a person to chase the missing approval.

The people a batch waits on

From last lab result to warehouse, hand-off by hand-off

Where 2.6 days on one batch file went at the fictional plant

Paper checklists, release modules and rule-driven review: three ways plants run this

Any of these can be run in house or with a contract partner. A contract manufacturer's QP, or a contract QP service, adds a written agreement and shared access to the mix. MHRA says there is "no regulatory requirement for the QP to be physically present at the site", and that remote certification must be controlled in the quality system.21 EMA says it could be allowed if the national authority accepts it, and that it takes place within the EU/EEA or Northern Ireland.8

Batch VL26-0418: from the last lab result at 7:52 am to a QP's signature at 10:58 am

In shortThis is the example from the top of the page, inside the product. Agents, AI helpers that each do one job, read the records and set six checkpoints: clear, to review, or blocked with an owner. Omar Haddad approves the one blocker. Lena Ortiz, the Qualified Person, reads the one item left, and she decides.

1

The last result arrives, and the signature is locked

Lena opens the release checkpoints. Across the top are the 8 batches in quarantine, each with six small status marks. Below sit this batch's six checkpoints: batch record, deviations, QC results and CoA (the certificate of analysis), environmental monitoring, changes and markets, stability. The seventh tile, QP certification, is locked.

The batch record review report is open on the right: 214 of 214 steps signed.

2

Specialist agents read seven systems, in view

One press starts the run. Each agent reports as it goes: 214 steps signed and 11 materials released; 2 deviations, one open; 17 of 17 results in specification with sterility no growth; 1,284 samples from the fill day; 48,210 identifiers uploaded.

Each tile fills in as its checks finish. The screen gives these timings for the sample run, and your own will differ.

3

One deviation stops its checkpoint, with a name beside it

The tile for deviations turns red, and the signature stays locked. DEV-26-1187: the formulated bulk was held 26 h 40 min against the batch record's 24-hour limit after a stopper-bowl jam. Study VR-114 supports 36 hours. The impact assessment concludes negligible impact, and QA approval is pending from Omar Haddad, due 12:00 pm.

Small numbers in the text link to the sentence in the source. The deviation report sits on the right, with that passage highlighted. Lena's button says "Ask Omar to approve".

4

Omar approves, and only that checkpoint re-checks

Omar gets the deviation with its cited records and the need date. At 10:42 am he approves: negligible impact, with the batch added to the ongoing stability program. That follows Annex 16 section 3's conditions in Part A.4 His approval clears the line. The decision on the batch stays with Lena.

The coordinating agent re-checks the deviations lines alone, and the tile turns green. An agent never closes a deviation.

5

One closed excursion comes to the QP to read

Environmental monitoring is amber, "to review". On the fill day, plate B-07 in room F-214 read 6 CFU per 4 hours against the Grade B limit of 5; the organism was Micrococcus luteus; every Grade A sample read 0; EM-26-0311 closed on October 3 with no impact. An open action-level investigation would block. A closed one reaches the QP as something to read.

6

She accepts it, and the signature tile opens

Lena reads the investigation and presses "Accept — no impact on the batch". The line now reads "Accepted by Lena Ortiz", and the acceptance goes on the record and the certificate. All six tiles are green, and the seventh turns dark and opens.

7

She certifies for five markets, with Canada off the list

The statement names the batch. The six checkpoints are listed, along with DE, FR, NL, ES and IT, and the note "Canada excluded — CC-26-0233". What cleared today is shown: DEV-26-1187 approved by Omar Haddad, EM-26-0311 accepted by her. She signs with the meaning "Certified for release (Annex 16)" and her password.

8

The register, the certificate and the stock follow her signature

Certificate QPC-2026-1043 is issued at 10:58 am. Then the steps she has just allowed run: the register entry is written, the signed PDF issued, the ERP status moves from Quarantine to Unrestricted for the five markets, and the warehouse and planner Priya Ranvelle are told. This is Annex 16's third act, and it follows her decision.4

9

The certificate names who accepted what

The drafted certificate became final only when Lena signed. It lists the markets, "not Canada" with its reason, the outcome of each checkpoint, the item she accepted and the signature block with her name, meaning and time.

10

Every step is on one trail, people and agents alike

The activity tab lists, newest first, what each person and agent did and when. An inspector asking how this batch got certified can read it top to bottom: AI steps are marked, and every human decision carries a name.

Market restrictions, lapsed supplier audits, open out-of-specification results and the release runway on screen

In shortOther batches show what else can stop a release: a change pending in one market, a lapsed supplier audit, an out-of-specification result in investigation. Further screens show every batch against its need date, each blocker by its owner, the register, the trends and the rules.

Eight release agents that read and draft, and the people whose signatures make it a decision

In shortA release coordinator and six specialists set the checkpoints, and a drafter prepares the certificate. Each has a job and a line it does not cross. Every decision belongs to a named person. Your checklist, and how close it stands to all 21 Annex 16 points, is yours to set.

The sample checklist's 18 lines against Annex 16's 21 points

Each checkpoint holds lines, 18 in the sample: six on the batch record, three on deviations, two on results, two on the clean room, four on changes and markets, one on stability. Together they cite 17 of the 21 points. Points 1.7.7 (active substance GMP), 1.7.8 (active substance import), 1.7.10 (TSE status) and 1.7.19 (self-inspection) have no line of their own in the sample, so add them to your own checklist, or record where your quality system already answers them.4 Section 1.6's personal duties stay with the QP.

Lena, Sam, Omar, Dana and Priya in the screens

From seven systems' records to a batch file with every blocker named, and what it is designed to reach

In shortThe solution reads the systems a batch's evidence already lives in, through read-only connections, and writes back status only after a signature. Its outcome numbers below are design targets on sample data, to be measured on your batches.

The systems a batch's evidence already lives in

Built for scale across plants, products and markets, with roles, maker-checker approvals (one person prepares, another approves), a full audit trail, export and integrations configured for each site. Your own batches, rules and people replace everything shown here.

What a blocker found late costs your plant in quarantine days, missed need dates and inspection exposure

In shortWe found no independent figure for what release delays cost, so this section shows you how to find yours in a week. Start with four numbers from your own systems: median days from made to certified, value in quarantine, how often batches are blocked on first look, and how many miss a need date.

Reading five recent batch files to find your own release baseline

QP fatigue, weak reliance and the deviation nobody saw

What faster release preparation returns: quarantine days, QA hours and need dates kept

In shortPut in your own numbers. The calculator values days taken out of quarantine, QA and QP hours you will reuse, and need dates kept. It subtracts the yearly cost. Every default is an assumption to replace, and the value rests on your own baseline.

Quarantine days, QA hours and kept need dates: where the value comes from

Batches a year, value in quarantine and hours per batch file

At these assumptions a small site with 50 batches a year barely covers the cost, and it may be better served by a clean checklist, a shared open-items list and a weekly look at need dates. A busy multi-product site clears it quickly, and its first question should be what the released hours are for. A cheap product changes the picture too: at low batch values, the carrying cost line fades and the case rests on hours.

How ready your release desk is: batch volume, connected systems, written rules and a QA position on AI

In shortPick the answer closest to your site today. Eight questions score 0 to 2, and the last is for reflection. The meter adds up your score as you go, and each question says why it matters and what a strong answer sounds like.

What to ask a batch release software vendor about evidence, blockers, signatures and draft Annex 22

In shortAsk every vendor the same questions, us included. The answers show whether a tool only tracks statuses or reads the records behind them, whose rules it applies, what it records, and how you would test it on your own batches.

A twelve-week batch release pilot: past files first, then live batches with the QP signing as usual

In shortTake 25 past batch files with known outcomes, and plant known blockers in copies of five. Write your rules against all 21 points. Run one product's live batches in parallel, with your desk working as usual and your QP deciding every one. Decide on three numbers: blockers missed, wrong citations and hours per file.

1. Measure first: time five batch files and pull the last 50 batches' days from final QC approval to certification.
2. Write the rules: one checklist against all 21 points, or 21 CFR 211, approved by your QPs, with what blocks and what the QP reads.
3. Replay 25 past files, including a planted lapsed audit, a planted market change and a planted open investigation.
4. Run one product live, in parallel, for five weeks. Your desk works as usual and your QP signs from your current process.
5. Decide on your numbers, with a written position from QA on Annex 22, a sampling plan and your validation approach.

Blockers missed, wrong citations and hours per batch file

Track all six measures. Blockers missed, wrong citations and hours per file are the three you decide on.

QP certification and batch disposition questions answered: Annex 16, deviations, the quality unit and software

In shortQuestions QPs, QA teams and buyers search for, each answered on its own.